Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaochaihu Keli is a traditional Chinese medicine (TCM) herbal formulation in granule form, developed and marketed by Huabao Pharmaceutical. It is based on the classical 'Xiao Chai Hu Tang' (Minor Bupleurum Decoction) formula, which dates back to the Shanghan Lun. The formulation consists of seven primary herbal ingredients: *Bupleurum chinense* (chaihu), *Scutellaria baicalensis* (huangqin), *Pinellia ternata* (banxia), *Codonopsis pilosula* (dangshen), *Glycyrrhiza uralensis* (gancao), *Zingiber officinale* (shengjiang), and *Ziziphus jujuba* (dazao). In TCM practice, it is indicated for harmonizing the Shao Yang stage, typically presenting as alternating chills and fever, chest discomfort, bitterness in the mouth, and nausea. As a complex herbal product, its therapeutic effects are attributed to the synergistic action of various phytochemicals rather than a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaochaihu Keli.